/
CERS
$2.99+$0.07 (+2.40%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$585.1M
200M shares
52-week range
$1.15 – $3.15
92% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-2.92
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $60.9M | $74.6M | $91.9M | $130.9M | $162.0M | $156.4M | $180.3M | $206.1M |
| Cost of revenue | $31.6M | $33.4M | $41.2M | $63.5M | $75.0M | $70.0M | $80.7M | $95.8M |
| Gross profit | $29.3M | $41.2M | $50.8M | $67.4M | $87.1M | $86.4M | $99.5M | $110.3M |
| Gross margin | 48.1% | 55.2% | 55.2% | 51.5% | 53.7% | 55.3% | 55.2% | 53.5% |
| R&D | $42.6M | $60.4M | $64.4M | $63.7M | $64.1M | $67.6M | $58.9M | $65.7M |
| Operating income | −$55.0M | −$66.2M | −$58.3M | −$48.9M | −$34.1M | −$30.1M | −$14.2M | −$36.3M |
| EBITDA | −$51.9M | −$64.6M | −$51.4M | −$46.0M | −$33.5M | −$26.3M | −$10.0M | −$4.9M |
| Net income | −$57.6M | −$71.2M | −$59.9M | −$54.4M | −$42.8M | −$37.5M | −$20.9M | −$15.6M |
| Net margin | -94.5% | -95.4% | -65.1% | -41.6% | -26.4% | -24.0% | -11.6% | -7.6% |
| EPS (diluted) | -0.44 | -0.51 | -0.37 | -0.32 | -0.24 | -0.21 | -0.11 | -0.08 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $253M | $-0.03 | $-0.04–$-0.03 | 2 |
| 2027 | $274M | $-0.00 | $-0.00–$-0.00 | 2 |
| 2028 | $312M | $0.10 | $0.10–$0.11 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.92
Price
$2.99
Implied downside
-2%
Peer comparison
Cerus Corp
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
www.cerus.com- Employees
- 345
- IPO / List date
- Jan 31, 1997
- HQ
- CONCORD, CA
Held by traders on TradeandTell
No one on the platform currently holds CERS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 578,900 | $1.1M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CERS yet.
